natgillin/translations-raw huggingface dataset:
treating the solution from step (c) with a strong, sterically hindered base to form a boron "ate" complex of formula (II): where M+ is a cation derived from the base, and each of Y and R1 to R5 are as defined above; and contacting the boron "ate" complex of formula (II) with a Lewis acid in a solution comprising an ether solvent that has low miscibility with water to form the boronic ester compound of formula (I), wherein the solubility of water in the ether solvent that has low miscibility with water is less than 5% w/w. 
ORs M I (ID) gdje je M" kation izveden od baze, i svako od Y i R' do R' su kao što su definirani u prethodnom tekstu; i (e) dovođenje u kontakt kompleksa borata formule (17) sa Lewis-ovom kiselinom u otopini koja sadrži etersko otapalo koje ima nisku mješavost sa vodom da bi se formirao spoj ester organoborne kiseline formule (7), pri čemu je otopljivost vode u eterskom otapalu koje ima nisku mješavost sa vodom manja od 5% tež./tež.
The pharmaceutical composition of claim 18, wherein the additional therapeutic agent is an anti-HIV drug. 
Farmaceutska smjesa prema zahtjevu 16, gdje dodatno terapijsko sredstvo ima djelovanje protiv HIV-a.
wherein PG is a hydroxyl protecting group. 
ib gdje je PG zaštitna skupina za hidroksi.
After being filtered, the procedure is repeated and then washed with DMF and IPA 3 times in turns, followed by 3 times washings with DMF. 
Nakon filtriranja, postupak se ponovi i zatim se ispere s DMF 1 IPA tri puta naizmjenično, a nakon toga još i tri puta sa DMF.
A preferred radiation is electron beam (“e-beam”) radiation. 
Poželjno zračenje je zračenje snopom elektrona ("e-snop").
The method of claim 1, wherein each first calibration data point is determined from a histogram corresponding to a different calibration sample, wherein a histogram provides amounts of DNA fragments at a plurality of sizes, and wherein at least a portion of the different calibration samples have different fractional concentrations. The method of claim 1, wherein measuring amounts of DNA fragments corresponding to the sizes includes: 
Metoda prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time, što: prva točka podataka za kalibraciju određuje frakcionalnu koncentraciju fetalne DNK koja odgovara kalibracijskoj vrijednosti prvog parametra; i točka podataka za kalibraciju se utvrđuje iz histograma koji odgovara različitom kalibracijskom uzorku, pri čemu histogram pruža količine fragmenata DNK u više veličina, i pri čemu najmanje jedan dio različitih kalibracijskih uzoraka ima različite frakcionalne koncentracije.
The pump may include: a discharge pump installed within the storage tank to discharge the LNG to the outside of the cargo tank; and a high pressure pump configured to secondarily compress the LNG, which is primarily compressed in the discharge pump, to a pressure necessary for the main engine. The sub LNG supply line may be branched from the main LNG supply line at an upstream side of the high pressure pump. 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 1, naznačen time što crpka uključuje: crpku za pražnjenje (2; 12), ugrađenu u skladišni spremnik radi pražnjenja LNG u vanjštinu spremnika za teret; i visokotlačnu (120;43) crpku, podešenu za sekundarno komprimiranje LNG, koji se primarno komprimira u crpki za pražnjenje, do tlaka potrebnog za glavni motor.
BCH-encoding PLP data to generate an error protected data; LDPC-encoding the BCH encoded PLP data; 
BHC-kodiranje PLP podataka zbog stvaranja podataka zaštićenih od pogreške; LDPC-kodiranje BHC-kodiranih PLP podataka;
An immunogenic composition comprising the recombinant virus of claim 1 in unit dose form. 
Cjepivo sadrži rekombinantni virus iz bilo kojeg od patentnih zahtjeva 1 do 6, u jediničnom obliku doziranja.
A compound according to the following formula (1), an enantiomer, diastereomer, tautomer, solvate, prodrug or pharmaceutical acceptable salt thereof wherein R is selected from the group consisting of COOR', CONR'R', tetrazolyl or H, with R' independently selected from the group consisting of H, lower alkyl; 
Spoj prema patentnom zahtjevu 1 gdje R je izabran iz grupe koju čini COORÂ«, CONR;Re, tetrazolil ili H, sa R4, R; i Rg nezavisno izabran iz grupe koju čini Hi C1galkil;
The method of claim 12, wherein the pinanediol boronic ester is obtained by reacting a bis-trimethylsilyl (TMS)2 amine derivative having the following structure: 
Postupak prema patentnom zahtjevu 8, naznačen time, da se pinandiol ester boronske kiseline dobiva putem reakcije bis-trimetilsilil (TMS)2 derivata amina koji ima sljedeću strukturu:
The method according to claim 1, wherein the pathological condition is selected from the group consisting of arthritis, inflammatory bowel diseases, eczema, and neurodermatitis. The method according to claim 1, where the pathological condition is vascularization triggered by breast cancer or by prostate cancer. 
Spoj namijenjen upotrebi u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je namijenjen sprječavanju 1li inhibiranju vaskulariziranja u upalnom stanju, osobito kada se upalno stanje bira iz skupine koju čine artritis, upalne bolesti crijeva, egzem, te neurodermatitis.
optionally, a multitude of administration units C containing dose c of tapentadol; wherein said multitude of administration units A is orally administered twice daily (bid) during a first administration interval of at least a consecutive days, said multitude of administration units B is orally administered twice daily (bid) during a second administration interval of at least B consecutive days following the first administration interval; and said optional multitude of administration units C is orally administered twice daily (bid) during a third administration interval of at least x consecutive days following the second administration interval; 
(ili) po izboru, mnoštvo jedinica za davanje C koje sadrže dozu c tapentadola, gdje se navedeno mnoštvo jedinica za davanje A daje oralno dvaput dnevno (bid) tijekom prvog intervala davanja od najmanje a uzastopna/ih dana, navedeno se mnoštvo jedinica za davanje B daje oralno dvaput dnevno (bid) tijekom drugog intervala davanja od najmanje B uzastopna/ih dana nakon prvog intervala davanja; i navedeno se fakultativno mnoštvo jedinica za davanje C daje oralno dvaput dnevno (bid) tijekom trećeg intervala davanja od najmanje x uzastopna/ih dana nakon drugog intervala davanja; gdje a, b, c ia, 6, x zadovoljavaju uvjet P, Q, R ili S:
Ph1 is phenyl optionally substituted with a substituent selected from the group consisting of halo, (C1-C2)alkyl optionally further substituted with 1 to 3 fluoro substituents, and (C1-C2)alkoxy optionally further substituted with 1 to 3 fluoro substituents; 
Ph1 je fenil, izborno supstituiran sa supstituentom kojeg se bira iz skupine koju čine halogen, (C1-C2)alkil, izborno dodatno supstituiran s 1 do 3 fluorna supstituenta, i (C1-C2)alkoksi, izborno dodatno supstituiran s 1 do 3 fluorna supstituenta;
A combination of a compound as defined in claims 1 to 3 with a second pharmaceutical active component selected from the classes of B2 agonists, M3 antagonists and corticosteroids. 
Kombinacija spoja formule (I) kao što je definirano u patentnim zahtjevima 1 do 7, naznačena time da je s drugom farmaceutski aktivnom komponentom odabranom od sljedećih: klasa 2 agonista, M3 antagnista i koritkosteroidi.
the tyrosine at position 10 of the FG loop (SEQ ID NO: 75) is substituted with W; or (xvii) the lysine at position 11 of the FG loop (SEQ ID NO: 75) is substituted with an amino acid selected from the group consisting of A, C, D, E, G, H, L, M, N, P, Q, R, S, T, and V. 
tirozin na položaju 10 u petlji FG (SEQ ID NO: 75) je zamijenjen aminokiselinom koju se bira iz skupine koju čine F ili W; ili (xi) - tirozin na položaju 11 u petlji FG (SEQ ID NO: 75) je zamijenjen aminokiselinom koju se bira iz skupine kojučine A, C,D,E,F,G,H,LK,L,M,N,P, Q,R, S, T, V ili W.
an average telomere length that is at least 30 percent of the telomere length of a hESC and/or human iPS cell (or the average of a population of hESC and/or human iPS cells), or at least 40, 50, 60, 70 80 or 90 percent of the telomere length of an hESC and/or human iPS cell; 
prosječna duljina telomera koja je barem 30 posto duljine telomera hESC-a i/ili humane iPS stanice (ili prosjeka populacije hESC-a i/ili humanih iPS stanica), ili barem, 40, 50, 60, 70, 80 ili 90 posto duljine telomera hESC-a i/ili humane iPS stanice;
Further, the phrase “in need of treatment” also refers to the “prophylaxis” of an individual which is the judgment made by the caregiver that the individual will become ill. 
Nadalje, fraza "u potrebi za liječenjem" se također odnosi na "profilaksu" pojedinca na osnovi prosudbe onog koji brine za njega da će se razboljeti.
In one embodiment of the invention there is provided a mushroom production process in which the fuel storage area comprises an open storage area adjacent the combustion apparatus. 
Postupak sukladno Zahtjevu 12 u kojem se prostor za skladištenje goriva (7) sastoji od otvorenog skladišnog prostora susjednog aparatu za spaljivanje.
An inhaler according to claim 7, wherein the medicament is selected from the group consisting of anti-inflammatory agents, anticholinergic agents, B2-adrenoreceptor agonists, anti-infective agents, antihistamines and combinations thereof, preferably wherein the medicament is selected from the group consisting of salbutamol, formoterol, salmeterol, fluticasone, budesonide, beclomethasone, tiotropium, ipratropium and combinations thereof. 
Inhalator u skladu s patentnim zahtjevom 7, pri čemu je lijek odabran iz grupe koja se sastoji od protuupalnih agenasa, antikolinergičkih agenasa, agonista f2-adrenoreceptora, protuinfektivnih agenasa, antihistaminika i njihovih kombinacija, poželjno gdje je lijek odabran iz grupe koja se sastoji od salbutamola, formoterola, salmeterola, flutikazona, budezonida, beklometazona, tiotropija, ipratropija i njihovih kombinacija.
The method of para 14, wherein inflammatory diseases are selected from rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, psoriatic arthritis, chronic obstructive pulmonary disease (COPD), inflammatory bowel diseases, pancreatitis, peripheral neuropathy, multiple sclerosis (MS) and inflammation associated with cancer. 
Spoj za uporabu prema patentnom zahtjevu 7, pri čemu su inflamatorne bolesti izabrane od reumatoidnog artritisa, osteoartritisa, ankiloznog spondilitisa, psorijatičnog artritisa, kronične opstruktivne bolesti pluća (COPD), inflamatornih bolesti crijeva, pankreatitisa, periferne neuropatije, multiple skleroze (MS) i inflamacije povezane sa karcinomom.
The antibody drug conjugate for use according to claim 13, wherein the cancer is selected from the group consisting of tumors of the central nervous system, head and neck cancer, lung cancer, such as NSCLC, breast cancer, specifically triple negative breast cancer, esophageal cancer, gastric or stomach cancer, liver and biliary cancer, pancreatic cancer, colorectal cancer, bladder cancer, kidney cancer, prostate cancer, endometrial cancer, ovarian cancer, malignant melanoma, sarcoma, tumors of unknown primary origin, bone marrow cancer, acute lymphoblastic leukemia, AML, chronic lymphoblastic leukemia and non-Hodgkin lymphoma, skin cancer, glioma, cancer of the brain, uterus, and rectum. 
Konjugat protutijela s lijekom za uporabu prema zahtjevu 13, naznačen time, da je rak odabran iz skupine koju čine tumori centralnog nervnog sustava, rak glave i vrata, rak pluća, kao što je primjerice NSCLC, rak dojke, osobito trostruko negativan rak dojke, rak jednjaka, gastrički rak ili rak želudca, rak jetre 1 žuči, rak pankreasa, kolorektalni rak, rak mjehura, rak bubrega, rak prostate, rak endometrija, rak jajnika, maligni melanom, sarkom, tumori nepoznatog primarnog podrijetla, rak koštane srži, akutna limfoblastna leukemija, AML, kronična limfoblastna leukemija i ne-Hodgkin-limfom, rak kože, gliom, rak mozga, uterusa i rektuma.
Fast cut-off circuit 4 comprises a first and a second AND logic gate 30, 31; an OR logic gate 32; and a first and a second threshold comparator 33, 34. 
Komunikacijski krug brzog prekidanja 4 sadrži prva i druga I (AND) logička vrata 30, 31; ILI (OR) logička vrata 32; te prvi i drugi uspoređivač na pragu 33, 34.
In case of injections there may be incorporated physiologically acceptable buffers, solubilizing agents or isotonics. 
U slučaju injekcija u njih se mogu umiješati fiziološki prihvatljivi puferi, sredstva za pospješivanje otapanja ili izotonici.
grinding the cathode in an impact grinder for providing a particulate cathode comprising metal foil particles having an average particle size of at least 200 µm and cathode material particles having an average particle size of less than 200 µm; 
(id) mljevenje katode u udarnoj drobilici za dobivanje usitnjenih čestica katode koje sadržavaju čestice metalne folije s prosječnom veličinom čestica od najmanje 200 um 1 čestice katodnog materijala koje imaju prosječnu veličinu čestica manju od 200 um;
A capsule according to any one of claims 1-2, wherein the at least one projection (28.i; 107; 117; 127; 137) is circumferential with respect to the capsule (2). 
Kapsula prema jednom od patentnih zahtjeva 1-2, pri čemu najmanje jedan ispupčeni dio (127) je raspoređen po obodu u odnosu na kapsulu (119).
An object of the present invention is particularly a method as defined above, for producing at least one fermentation product, preferably ethanol, characterized in that said fermentation medium comprises at least one hydrolyzate of all or part of a plant material. 
Postupak u skladu s patentnim zahtjevom 8 ili patentnim zahtjevom 9, naznačen time što navedeni fermentacijski medij sadrži najmanje jedan hidrolizat cijelog ili dijela biljnog materijala.
The compositions according to claim 7 in the form of injectable preparations or of topical preparations for epidermal, transdermal or ophthalmic application. 
Sastavi u skladu s patentnim zahtjevom 7 u obliku injektibilnih pripravaka ili topikalnih pripravaka za epidermanu, transdermalnu ili oftalmološku primjenu.
Other embodiments of physiological conditions that can be treated by the present invention include physiological conditions such as chronic obstructive pulmonary disease (COPD), COPD exacerbations, joint cartilage destruction, ocular conjunctivitis, vernal conjunctivitis, inflammatory bowel disease, asthma, allergic rhinitis, interstitial lung diseases, fibrosis, scleroderma, pulmonary fibrosis, liver cirrhosis, myocardial fibrosis, neurofibromas, hypertrophic scars, various dermatological conditions, for example, atopic dermatitis and psoriasis, myocardial infarction, stroke, angina and other consequences of atherosclerotic plaque rupture, as well as periodontal disease, diabetic retinopathy, tumour growth, anaphylaxis, multiple sclerosis, peptic ulcers, and syncytial viral infections. 
Spoj prema zahtjevu 1 naznačen time da je za uporabu u liječenju fiziološkog stanja koje je potrebno ublažiti inhibicijom triptaze, pri čemu je fiziološko stanje odabrano iz skupine koju čine upalna bolest, bolest destrukcije zglobne hrskavice, očni konjunktivitis, proljetni konjunktivitis, upalna crijevna bolest, astma, alergijski rinitis, intersticijska bolest pluća, fibroza, kronična opstruktivna plućna bolest, sklerodermija, plućna fibroza, ciroza jetre, fibroza miokarda, neurofibrom, hipertrofični ožiljak, dermatološko stanje, stanje povezano s pucanjem aterosklerotičnog plaka, periodontalna bolest, dijabetička retinopatija, rast tumora, anafilaksija, multipla skleroza, peptički ulkus, te sincicijska virusna infekcija.
An ex-vivo method for testing whether a patient will respond therapeutically to a method of treatment comprising administration of an immunogenic composition, wherein the testing method comprises the step of measuring levels of sICAM-1 in a blood sample obtained from said patient before administration of said immunogenic composition wherein low levels of sICAM-1 indicate that the patient will develop a prophylactic or therapeutic response towards the immunogenic composition with low levels of sICAM-1 being fewer than 300 ng/ml, and wherein said immunogenic composition contains all or part of at least one targeted antigen or at least one recombinant vector expressing in vivo all or part of at least one heterologous nucleotide sequence encoding all or part of at least one targeted antigen. 
Postupak ispitivanja ex-vivo hoće li pacijent odgovoriti terapijski na postupak liječenja koji se sastoji u primjeni imunogenog pripravka, naznačen time što se postupak ispitivanja sastoji u koraku mjerenja razina sICAM-1 u uzorku krvi uzetom iz navedenog pacijenta prije primjene navedenog imunogenog pripravka, gdje niske razine sICAM-I ukazuju da će pacijent razviti profilaktički ili terapijski odgovor na imunogeni pripravak kada su niske razine sICAM-I ispod 300 ng/ml, te što navedeni imunogeni pripravak sadrži sve ili dio najmanje jednog ciljanog antigena ili najmanje jedan rekombinantni vektor koji in vivo eksprimira sve ili dio najmanje jednog heterolognog nukleotidnog slijeda koji kodira sve ili dio najmanje jednog ciljanog antigena.
comparing the measured parameter value with a predetermined parameter value, and providing the amount of injected solution derived from calcium carbonate on the basis of the difference between the measured and the predetermined parameter value. 
€) uspoređivanje izmjerene parametarske vrijednosti s predodređenom parametarskom vrijednosti, te f) osiguravanje količine ubrizgane otopine koja je dobivena iz kalcijevog karbonata na temelju razlike između izmjerene i predodređene parametarske vrijednosti.
The assembly of claim 1 or 2, wherein the first (13) and second (14) jaw members are pivotally attached adjacent said inlet (16) for relative angular movement to alter said height (38). 
Sklop u skladu s patentnim zahtjevom 1 ili 2, naznačen time što su prvi (13) i drugi (14) čeljusni element zakretljivo pričvršćeni uz navedeni ulaz (16) kako bi se omogućilo relativno kutno gibanje radi mijenjanja navedene visine (38).
The dosage form according to any of claims 1 to 7, wherein the enteric coated pellets are consisting of the structural components; a core material comprising the active ingredient, a subcoating layer, an enteric coating layer and no additional coating layer on the enteric coat 
Oblik doziranja prema bilo kojem od zahtjeva 1 do 7, naznačen time da se želučano otporni peleti sastoje od slijedećih komponenti: materijala jezgre koji sadrži djelatnu tvar, sloja pod-sloja, želučano otpornog sloja, te nema dodatnog sloja na želučano otpornom sloju.
A foamed rigid polymer product prepared from the resin composition according to claims 1 to 8. 
Pjenasti kruti polimerni produkt pripravljen iz smolastog sastava prema zahtjevima 1 do 11.
represents -(SO2)OH or -O-(SO2)OH, X represents CH, Z represents an alkyl-chain having two or three carbon atoms, whereby the alkyl-chain may be substituted with one or two substituents, selected independently of one another from the group consisting of carboxy and methyl, 
predstavlja -(SO2)OH ili -O-(SO2)OH, X predstavlja CH, Z predstavlja alkilni lanac s dva ili tri atoma ugljika, gdje alkilni lanac može biti supstituiran s jednim ili dva supstituenta, koje se međusobno neovisno bira iz skupine koju čine karboksi i metil, Y predstavlja O, A predstavlja fenil ili 6-eročlani heteroaril, gdje su fenil i heteroaril supstituirani sa supstituentom sljedeće formule [image], gdje
suffering from a TTR-associated disease; or at risk for developing a TTR-associated disease. The agent or composition for use of any one of claims 13 to 16, wherein said subject carries a TTR gene mutation that is associated with the development of a TTR-associated disease, wherein preferably said TTR-associated disease is selected from the group consisting of senile systemic amyloidosis (SSA), systemic familial amyloidosis, familial amyloidotic polyneuropathy (FAP), familial amyloidotic cardiomyopathy (FAC), leptomeningeal/Central Nervous System (CNS) amyloidosis, and hyperthyroxinemia. 
Sredstvo ili pripravak za uporabu prema bilo kojem od patentnih zahtjeva 11 do 14, naznačeni time što se navedeni subjekt nosi mutaciju gena TTR koja je povezana s razvojem bolesti povezane s, pri čemu je poželjno navedena bolest povezana s TTR odabrana iz skupine koja sadrži senilnu sistemsku amiloidozu (SSA), sistemsku obiteljsku amiloidozu, obiteljsku amiolidotičnu polineuropatiju (FAP), obiteljsku amiolidotičnu kardiomiopatiju (FAC), leptomeningealnu amiloidozu / amiloidozu središnjeg živčanog sustava (CNS), i hipertiroksinemiju.
Tapentadol for use in the prevention of chronification of pain. 
PATENTNI ZAHTJEVI Tapentadol za upotrebu u prevenciji kronifikacije boli.
Block according to any one of the preceding claims, applied to a peripheral edge of a lavatory bowl or toilet through a hook directly inserted into the body of the block or by means of an applicator device external to the block. 
Blok u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se stavlja na obodni rub zahodske školjke ili toaleta uz pomoć kuke izravno usađene u tijelo bloka, ili uz pomoć aplikatorskog uređaja koji nije dio bloka.
The cell according to claim 24, wherein the antibody specific for the protofibrillar form of the A-B peptide comprises a heavy chain set forth as SEQ ID NO: 26 and a light chain set forth as SEQ ID NO: 22. 
teški lanac koji se sastoji od polipeptidnog slijeda SEQ ID NO: 2 i laki lanac koji se sastoji od polipeptidnog slijeda SEQ ID NO: 22, ili
a scheduling unit; and a transmitting unit configured to transmit, to the mobile station apparatus, the PDCCH in the search space, wherein the PDCCH includes both a C-RNTI for persistent scheduling and resource allocation information set to a predetermined value when a mobile station apparatus has both the C-RNTI for dynamic scheduling and the C-RNTI for persistent scheduling, wherein the PDCCH is designated to be searched in the search space, the search space being located by the mobile station apparatus according to the C-RNTI for dynamic scheduling, and wherein the PDCCH is further designated to be decoded by the mobile station apparatus according to the C-RNTI for persistent scheduling, and wherein the predetermined value of the resource allocation information is designated to direct the mobile station apparatus to halt data transmission on persistently-allocated resources. 
Uređaj bazne stanice koji je prilagođen za odašiljanje, na uređaj mobilne stanice, kontrolnog kanala fizičke silazno veze, PDCCH, u prostoru pretraživanja, naznačen time da uređaj bazne stanice sadrži: sredstva podešena za odašiljanje na uređaj mobilne stanice, u prostoru pretraživanja, te PDCCH sadrži identitet prve mobilne stanice ili identitet druge mobilne stanice, pri čemu je prostor pretraživanja određen na temelju identiteta prve mobilne stanice, u slučaju da uređaj mobilne stanice ima identitet prve mobilne stanice i identitet druge mobilne stanice; PDCCH se koristi za dinamično raspoređivanje kada PDCCH sadrži identitet prve mobilne stanice; a PDCCH se koristi za aktiviranje trajnog raspoređivanja kada PDCCH sadrži identitet druge mobilne stanice.
wherein the first cationic lipid and the second cationic lipid are non-identical; and wherein expression of a protein or peptide encoded by the mRNA following the administration of the pharmaceutical composition to the subject exceeds expression of the protein or peptide encoded by the otherwise identical amount of mRNA administered with the first lipid nanoparticle but without the second lipid nanoparticle by at least about two-fold. 
Farmaceutski pripravak za isporuku polinukleotida tipa informacijske RNK (iRNK) do jedne ili više ciljnih stanica, naznačen time da navedeni pripravak sadrži iRNK i mješavinu najmanje prve lipidne nanočestice i druge lipidne nanočestice, pri čemu prva lipidna nanočestica sadrži iRNK; i pri čemu prva lipidna nanočestica sadrži najmanje jedan lipid jasno različit od druge lipidne nanočestice.